Qcca Network LLC

1. AstraZeneca Pharmaceuticals LP $769,814 19 payments
2. Boehringer Ingelheim Pharmaceuticals, Inc. $377,196 4 payments
3. Genentech, Inc. $373,565 59 payments
4. Mirati Therapeutics, Inc. $240,921 42 payments
5. Eli Lilly and Company $212,372 7 payments
6. Day One Biopharmaceuticals $95,499 104 payments
7. ADC Therapeutics America, Inc. $93,163 10 payments
8. AbbVie, Inc. $84,367 22 payments
9. Sanofi US Services Inc. $82,425 18 payments
10. Aveo Pharmaceuticals, Inc. $74,699 38 payments

1. A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole $390,281 14 payments
2. Phase 2 HR+ breast cancer xentuzumab + everolimus $377,196 4 payments
3. A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) $368,768 4 payments
4. T Dm1 Atezolizumab in High Risk Her2 Patients With Residual Disease $317,849 52 payments
5. A Phase 3 Open-Label Randomized Study of Pirtobrutinib (Loxo-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Bruin-Cll-314) $139,661 3 payments
6. A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy $102,110 10 payments
7. A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations $95,499 104 payments
8. A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) $82,858 6 payments
9. A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease $82,425 18 payments
10. TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor $74,699 38 payments

1. Non-patient care $67,268 26 payments
2. Patient care $67,030 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.